|
6-7 |
PEDIATRIA |
L.V. Osidak, O.I. Afanasyeva, E.G. Golovacheva, E.A. Smorodintseva, E.V. Obraztsova, E.S. Goncharova
Rimantadine in combination with sodium alginate as a means of treatment and prevention of acute respiratory viral infections of various etiologies in infants and preschool children
|
8-14 |
E.B. Belan, E.M. Nikiforova
Possibility of using a combination of interferon alpha-2b and a complex immunoglobulin drug for infectious diseases in children
|
15-18 |
O.A. Bashkina, D.F. Sergienko, T.M. Kuznetsova
Bronchiolitis in children: a series of clinical examples
|
19-24 |
|
N.V. Sturov, S.V. Popov, Z.A. Ivanov
Disturbances of the gut microbiota and their correction in patients with oxalate nephrolithiasis
|
25-31 |
D.I. Trukhan, V.A. Gudilin
Antibiotic-associated diarrhea: potentials for the use of synbiotics
|
32-39 |
Yu.P. Uspensky, Z.Kh. Gulunov
Upper gastrointestinal involvement in Crohn’s disease
|
40-43 |
N.A. Fadeeva, O.V. Knyazev, D.S. Bordin, K.A. Nikolskaya, S.M. Chudnykh, N.A. Dashkina, G.B. Artykova, E.I. Aliev
Features of the use of genetic engineering biological drugs in the treatment of patients with Crohn’s disease
|
44-48 |
S.V. Zakharov, A.Yu. Savchenko
Therapeutic horizons of indirect oral anticoagulants
|
50-56 |
O.D. Ostroumova, A.V. Dubinina, V.A. De, A.I. Kochetkov, V.B. Dashabylova, S.S. Eremina, M.V. Klepikova
On the issue of improving the safety of antithrombotic therapy in patients with atrial fibrillation and coronary heart disease receiving antithrombotic therapy
|
57-67 |
A.V. Dubinina, A.I. Kochetkov, A.E. Vorobyova, S.S. Eremina, K.B. Mirzaev, O.D. Ostroumova
Analysis of the structure of comorbidities and pharmacotherapy in patients with a combination of atrial fibrillation and coronary heart disease
|
68-77 |
E.V. Rebrova, E.V. Shikh, R.E. Kazakov, G.G. Melkonyan, N.P. Kulagina
Analysis of the frequency of CYP2C9, AGTR1, AGT, ACE, CYP11B2 gene Polymorphisms occurrence in patients with newly diagnosed 1–2 degree arterial hypertension
|
78-86 |
M.V. Leonova
Bempedoic acid – a new drug in lipid-lowering therapy
|
88-94 |
I.G. Trukhanova, S.Kh. Sadreeva, D.S. Zinatullina, I.A. Polyakov, D.P. Alcova
Clinical case of complete atrioventricular block complicated by Morgagni-Adams-Stokes syndrome at the prehospital stage
|
95-99 |
E.G. Bykova, O.V. Zakharova, N.A. Platonava
Endovascular treatment of a patient with chronic abdominal ischemia syndrome: a clinical case
|
100-105 |
E.Yu. Trushina, E.M. Kostina, V.A. Tipikin, E.A. Orlova
Modern ideas about the combination of bronchial asthma and chronic obstructive pulmonary disease
|
106-110 |
A.Y. Savchenko, G.V.Ramenskaya, V.G. Kukes, N.V. Shilova
Evaluation of the effectiveness of the new anti-tuberculosis drug thiozonide in patients with pulmonary tuberculosis with multi- and extensive drug resistance of Mycobacterium tuberculosis
|
112-117 |
N.L. Ryabkova, E.B. Moskvina
Dynamics of antibiotic resistance in the surgical departments of a multidisciplinary hospital using the example of the Republican Hospital n.a. V.A. Baranov
|
118-123 |
E.V. Panteleev, S.V. Matveev
Personalized approach to the rehabilitation of patients with degenerative dystrophic disk disease and clinical manifestations in the form of poor posture and pain syndrome
|
124-129 |
DERMATOLOGY / ALLERGOLOGY |
E.M. Markelova, L.S. Kruglova, N.V. Gryazeva
Experience with the use of various forms of zinc pyrithione for seborrheic dermatitis
|
130-134 |
E.V. Svechnikova, Yu.V. Maksimova, G.B. Arutyunyan, N.O. Artemyeva, A.V. Devyatova, A.A. Sherf
Seborrheic dermatitis. association of MCM6 lactase gene polymorphism and seborrheic dermatitis by the example of a clinical case
|
135-137 |
Oncology |
F.G. Ivanova, T.I. Nikolaeva, N.I. Spiridonova, L.N. Afanasyeva, P.V. Nikiforov, T.N. Zharnikova
Clinical experience with the use of combination drug therapy in the first line treatment of metastatic non-small cell lung cancer
|
138-142 |
G.G. Khakimova, A.A. Tryakin
Data in the treatment of colon cancer from real clinical practice in Tashkent, Uzbekistan
|
143-148 |
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.V. Komyakhov, A.S. Emelyanov, A.O. Gorina
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
|
149-152 |